AcuteCare Telemedicine and the Bon Secours Neuroscience Institute established a collaborative partnership earlier this year to enhance BSNI's "around the clock" neurological service. The fourth largest and only faith-based health system in Virginia, Bon Secours Virginia offers a full range of services including cardiac, women's, children's,...
BASEL- ACADIA Pharmaceuticals Inc. has submitted a New Drug Application to the FDA seeking approval for NUPLAZID for the treatment of psychosis associated with Parkinson's disease. Allergan plc has opened its purse strings yet again- this time to acquire privately-held glaucoma treatment company AqueSys Inc.. In the United States, XEN45 is in late-
Release date- 03092015- AstraZeneca today announced that the US Food and Drug Administration has approved BRILINTA tablets at a new 60 mg dose to be used in patients with a history of heart attack beyond the first year. BRILINTA is an oral antiplatelet treatment that works by inhibiting platelet activation and was first approved by the FDA in July
LONDON- AstraZeneca PLC late on Thursday said the US Food and Drug Administration has approved its Brilinta tablets at a new 60 miligram dose to be used in patients with a history of heart attacks beyond the first year of treatment. The FTSE 100 drugmaker said that with the expanded indication Brilinta is now approved as a treatment for reducing th
Chugai Pharmaceutical Co., Ltd. announced today that the US Food and Drug Administration has granted the Breakthrough Therapy Designation to ACE910, for the prophylactic treatment of people who are 12 years or older with hemophilia A with factor VIII inhibitors. We are very pleased that the FDA has granted Breakthrough Therapy Designation
Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients, today announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The combined revenue from these transactions is ov
Office Address: Department of Health and Human Services; Indian Health Service; Northern Navajo Medical Center; PO Box 160 US Highway 491 North Shiprock NM 87420-0160. Contact: Philoma Singer, Phone 5053687031, Email email@example.com. Description: Department of Health and Human Services.
Corbus Pharmaceuticals Holdings reported that patient enrollment has commenced in the Phase 2 clinical study of its investigational new drug Resunab for the treatment of diffuse cutaneous systemic sclerosis. There are currently no FDA- approved drug therapies specifically for systemic sclerosis, the company noted. The study is being led by principa
FDA approves Cosmo's submucosal injectable composition SIC 8000. Luxembourg, Luxembourg- September 4, 2015- Cosmo Pharmaceuticals S.p.A. announced today that the FDA has approved its request for marketing authorization of SIC 8000, its submucosal injectable composition.. Alessandro Della Ch, CEO of Cosmo Pharmaceuticals, commented: "I am very ple
WASHINGTON, Sept. 4 The Department of Health& Human Services published the following rule in the Federal Register from the Food& Drug Administration:. A Rule by the Food and Drug Administration on 09/04/2015. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where app
By a News Reporter-Staff News Editor at Health& Medicine Week Fresh data on Rheumatoid Arthritis are presented in a new report. According to news reporting originating from Rome, Italy, by NewsRx correspondents, research stated, "To assess anakinra as a therapy for systemic juvenile idiopathic arthritis in a single-center series. Our news editors
Findings on Critical Care Medicine Discussed by Investigators at Royal Liverpool University Hospital. According to news reporting originating in Liverpool, United Kingdom, by NewsRx journalists, research stated, "Demand for intensive care is growing. The news reporters obtained a quote from the research from Royal Liverpool University Hospital, "..
GlycoMimetics reported that the U.S. Patent and Trademark Office has issued a composition of matter patent, entitled "E-Selectin Antagonist Compounds, Compositions and Methods of Use," which provides coverage for the chemical structure of GlycoMimetics' clinical product candidate GMI-1271. "This patent issuance represents an important step for...
Mitralign reported that the U.S. Food and Drug Administration has granted Investigational Device Exemption approval for the Company to conduct an early feasibility study to examine its Percutaneous Tricuspid Valve Annuloplasty System. "Percutaneous repair of the tricuspid valve represents one of the largest remaining unmet needs in the structural.
FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5689, firstname.lastname@example.org.
By a News Reporter-Staff News Editor at Insurance Weekly News New York University College of Nursing's Tara Cortes, PhD, RN, FAAN, professor of geriatric nursing and executive director of the Hartford Institute for Geriatric Nursing, has been awarded a 3- year $2.55 million Health Resources and Services Administration grant through the Geriatrics
Report Summarizes Hemorrhagic Transformation Study Findings from University Medical Center. According to news reporting originating in Utrecht, Netherlands, by NewsRx journalists, research stated, "Intravenous thrombolysis can improve clinical outcome in acute ischemic stroke patients but increases the risk of hemorrhagic transformation.
By a News Reporter-Staff News Editor at Drug Week Investigators publish new report on Molecular Imaging. According to news originating from Geneva, Switzerland, by NewsRx correspondents, research stated, "Hypoxia, a condition of insufficient oxygen availability to support metabolism, occurs when the vascular supply is interrupted, as in stroke.
Secretarial Review and Publication of the Annual Report to Congress and the Secretary Submitted by the Consensus-Based Entity Regarding Performance Measurement. SUMMARY: This notice acknowledges the Secretary of the Department of Health and Human Services' receipt and review of the 2015 Annual Report to Congress and the Secretary submitted by the..
By a News Reporter-Staff News Editor at Science Letter Investigators publish new report on Science. According to news reporting originating from London, United Kingdom, by NewsRx correspondents, research stated, "Faecal microbiota transplantation is effective in the treatment of Clostridium difficile infection, where efficacy correlates with chan
Sun BioPharma reported that the U.S. Food and Drug Administration has granted Investigational New Drug status to its lead development candidate, SBP-101, a polyamine analogue compound licensed from the University of Florida with therapeutic potential for both pancreatic cancer and pancreatitis indications. As a result of FDA acceptance of the IND,
The Critical Path Institute reported that the U.S. Food and Drug Administration has issued a qualification decision in the form of a draft guidance to C-Path's Polycystic Kidney Disease Outcomes Consortium for total kidney volume as a prognostic biomarker to select patients for clinical trials of new therapies for Autosomal Dominant Polycystic Kidn
Titan Pharmaceuticals reported the resubmission by Braeburn Pharmaceuticals of a New Drug Application to the U.S. Food and Drug Administration for Probuphine, Titan's subdermal implant containing buprenorphine HCl for the maintenance treatment of opioid addiction. "We are extremely pleased by the Braeburn and Titan teams' expeditious preparation o
Release date- 03092015- Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has granted breakthrough therapy designation to ACE910 for the prophylactic treatment of people who are 12 years or older with hemophilia A with factor VIII inhibitors. Genentech has been developing antibody treatments for peop
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has granted breakthrough therapy designation to ACE910 for the prophylactic treatment of people who are 12 years or older with hemophilia A with factor VIII inhibitors. Genentech has been developing antibody treatments for people with blood disorders